DESIGN AND EVALUATION OF MODIFIED CHITOSAN BASED IN SITU GEL FOR OCULAR DRUG DELIVERY
Objective: The object of the present study was to formulate and evaluate in-situ gel of modified chitosan by using temperature triggered method to improve bioavailability.
Methods: Modified chitosan-based moxifloxacin HCl was prepared by cold method. polaxomer 407 adding in distilled water and this solution kept in the refrigerator. Modified chitosan and moxifloxacin HCl was dissolved separately in distilled water and added to the polymeric solution with continuous stirring until thoroughly mixed. Prepared formulation was evaluated for drug content, gelling capacity, rheological study, in vitro drug release behavior, measurement of phase change temperature, antibacterial study, release kinetics, statistical analysis.
Results: The prepared formulations were evaluated for their, drug content, gelation temperature, in vitro drug release studies, rheological study and release kinetics. All batches of in situ formulations had satisfactory pH ranging from 6.2Â±0.2, drug content between 98.8Â±0.2 showing uniform distribution of drug. As the concentration of each polymeric component was increased, there was a decrease in phase change temperature. The in vitro drug release decreased with increase in polymeric concentrations. The antibacterial efficiency of the selected formulation against staphylococcus aureus confirmed that designed formulation has prolonged effect and retained its properties against bacterial infection.
Conclusion: The prepared in situ gelling formulation had the appropriate combination of polaxomer 407 and modified chitosan were suitable satisfactorily sustained the drug release from moxifloxacin HCl in situ gel. The prepared formulation of moxifloxacin HCl appears to be promising drug delivery for bacterial infectious disease.
2. Anshul S, Renu SA. Review on levofloxacin in the situ-gel formulation. Asian J Pharm Clin Res 2015;8:37-41.
3. Tais G, Guilherme MG, Eduardo MR, Sarmento VH, Freitas OD, Lopez RFV. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010;75:186â€“93.
4. Chaudhary B, Verma S. Preparation and evaluation of novel in situ gels containing acyclovir for the treatment of oral herpes simplex virus infections. Sci world J 2014:1â€“7. http:// dx.doi.org/10.1155/2014/280928.
5. Kumar S, Kavitha K, M Rupeshkumar, Jagadeesh Singh SD. Thermo and PH responsive ocular in situ gels formulation: based on combination with natural polymers. Am J Pharmtech Res 2013;3:290â€“301.
6. Mandal S, Thimmasetty MKMJ, GL Prabhushankar, MS Geetha. Formulation and evaluation of an in situ gel-forming ophthalmic formulations of moxifloxacin hydrochloride. Int J Pharm Investig 2012;2:78â€“82.
7. Wagh VD, Deshmukh KH, Wagh KV. Formulation and evaluation of in situ gel drug delivery system of sesbania grandiflora flower extract for the treatment of bacterial conjunctivitis. Pharm Sci Res 2012;4:1880â€“4.
8. Bhoyar BS, Agnihotri VV, Bodhankar MM. Design of polyoxyethylene-polyoxypropylene block co-polymer based in situ gelling system for localized ocular drug delivery. Int J Res Pharm Chem 2011;1:591-600.
9. Swamy SP, Sanjeri F, Nadaf A, Jamakandi VG, Mulla JS. Formulation and evaluation of a novel in situ gum based ophthalmic drug delivery system of linezolid. Sci Pharm 2007;76:516â€“32.
10. Reddy JS, Ahmed MG. Sustained ocular delivery of sparfloxacin from pH Triggered in situ gelling system. Mahidol Univ J Pharm Sci 2013;40:16â€“25.
11. Sampathi S, Sharma J, Kaur R, Saini V. Design development and characterization: in situ gel of lomefloxacin hydrochloride for ocular drug delivery. World J Pharm Sci 2014;3:2350â€“64.
12. Sharma A. Development and characterization of in situ oral gel of spiramycin. BioMed Res Int 2014:1â€“7. http:// dx.doi.org/10.1155/2014/876182
13. Saxena P, Swatantra KS, Kyshwaha. PH sensitive hydrogel of levofloxacin hemihydrate for opthalmic drug delivery. World J Pharma Res 2014;3:4003-21.
14. Pawar P, Kashyap H, Malhotra S, Sindhu R. Hp-ð›½-CD-Voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment. BioMed Res Int 2013:1-9. http://dx.doi.org/10.1155/2013/341218
15. Kanoujia J, Sonker K, Pandey M, Kymonil KM, Saraf SA. Formulation and characterization of a novel ph-triggered in-situ gelling ocular system containing gatifloxacin. Int Curr Pharm J 2012;4:34-43.
16. Hongyi Q, Wenwen C, Chunyan H, Chuming C, Wenmin L, Chunjie W. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm 2007;337:178â€“87.
17. Reddy RK, M Srinivas, R Srinivas. Once-daily sustained-release matrix tablets of nicorandil: Formulation and in vitro evaluation. AAPS PharmSciTech 2003;4:480-8.
18. Maheswaran A, Padmavathy J, Nandhini V, Saravanan D, Angel P. Formulation and evaluation of floating oral in situ gel of diltiazem hydrochloride. Int J Appl Pharm 2017;9:50-3.
19. Laddha UD, Mahajan HS. An insight to ocular in situ gelling systems. Int J Appl Pharm 2017;6:31-40.